Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis

American Journal of Surgical Pathology

Volumn 34, Issue 3, 2010, Pages 364-370

  Basturk, Olca ^a   Khayyata, Said ^c   Klimstra, David S ^b   Hruban, Ralph H ^d   Zamboni, Giuseppe ^e   Coban, Ipek ^f   Adsay, Nazmi Volkan ^f  

^a NEW YORK UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF VERONA   (Italy)

^f EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Intestinal; Intraductal; Intraductal papillary mucinous neoplasm; MUC6; Mucinous cystic neoplasm; Pancreas; Papilla; Pyloric

Indexed keywords

MUC6 PROTEIN, HUMAN; MUCIN 6; TUMOR MARKER;

ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOMA IN SITU; CHEMISTRY; DISEASE COURSE; HUMAN; IMMUNOHISTOCHEMISTRY; MORTALITY; PANCREAS CARCINOMA; PAPILLARY CARCINOMA; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL; TIME; TREATMENT OUTCOME;

CARCINOMA IN SITU; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MUCIN-6; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77649197079     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181cf8bb6     Document Type: Article

References (27)

1. Adsay NV, Adair CF, Heffess CS, et al. Intraductal oncocytic papillary neoplasms of the pancreas. Am J Surg Pathol. 1996;20: 980-994.
2. Adsay NV, Merati K, Andea A, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol. 2002;15:1087-1095.
3. Adsay NV, Merati K, Nassar H, et al. Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas. Am J Surg Pathol. 2003;27:571-578.
4. Adsay NV, Merati K, Basturk O, et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol. 2004;28:839-848.
5. Furukawa T, Kloppel G, Adsay NV, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Archiv. 2005;447:794-799.
6. Furukawa T, Hatori T, Fukuda A, et al. Intraductal tubular carcinoma of the pancreas: case report with molecular analysis. Pancreas. 2009;38:235-237.
7. Khalifeh I, Basturk O, Zamboni G, et al. Villous-intestinal differentiation and progression to colloid carcinoma, characteristic of a major subset of IPMNs, are not features of mucinous cystic neoplasms. Modern Pathol. 2005;18:281A.
8. Kim GE, Bae HI, Park HU, et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology. 2002;123:1052-1060.
9. Klimstra DS, Adsay NV, Dhall D, et al. Intraductal tubular carcinoma of the pancreas: clinicopathologic and immunohisto-chemical analysis of 18 cases. Mod Pathol. 2007;20:285A.
10. Lee CS, Sund NJ, Vatamaniuk MZ, et al. Foxa2 controls Pdx1 gene expression in pancreatic beta-cells in vivo. Diabetes. 2002;51: 2546-2551.
11. Li XL, Eishi Y, Bai YQ, et al. Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol. 2004; 24:257-263.
12. Luttges J, Zamboni G, Longnecker D, et al. The immunohisto-chemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol. 2001;25:942-948.
13. Matsuzawa K, Akamatsu T, Katsuyama T. Mucin histochemistry of pancreatic duct cell carcinoma, with special reference to organoid differentiation simulating gastric pyloric mucosa. Hum Pathol. 1992; 23:925-933.
14. Nagata K, Horinouchi M, Saitou M, et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg. 2007;14:243-254.
15. Nakamura A, Horinouchi M, Goto M, et al. New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy. J Pathol. 2002; 197:201-210.
16. Nassar H, Pansare V, Zhang H, et al. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol. 2004;17:1045-1050.
17. Nishigami T, Onodera M, Torii I, et al. Comparison between mucinous cystic neoplasm and intraductal papillary mucinous neoplasm of the branch duct type of the pancreas with respect to expression of CD10 and cytokeratin 20. Pancreas. 2009;38:558-564.
18. Rouzbahman M, Serra S, Adsay NV, et al. Oncocytic papillary neoplasms of the biliary tract: a clinicopathological, mucin core and Wnt pathway protein analysis of four cases. Pathology. 2007;39: 413-418.
19. Sakai H, Jinawath A, Yamaoka S, et al. Upregulation of MUC6 mucin gene expression by NFkappaB and Sp factors. Biochem Biophys Res Commun. 2005;333:1254-1260.
20. Shibahara H, Tamada S, Goto M, et al. Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. Am J Surg Pathol. 2004;28:327-338.
21. Tanaka M, Fukushima N, Noda N, et al. Intraductal oncocytic papillary neoplasm of the bile duct: clinicopathologic and immunohistochemical characteristics of 6 cases. Hum Pathol. 2009;40: 1543-1552.
22. Terris B, Dubois S, Buisine MP, et al. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions. J Pathol. 2002;197:632-637.
23. Wang Z, Banerjee S, Li Y, et al. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006;66:2778-2784.
24. Yamaguchi H, Shimizu M, Ban S, et al. Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2009;33:1164-1172.
25. Yonezawa S, Nakamura A, Horinouchi M, et al. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg. 2002;9: 328-341.
26. Yonezawa S, Goto M, Yamada N, et al. Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics. 2008;8: 3329-3341.
27. Zhang Y, Banerjee S, Wang Z, et al. Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer. Cancer Res. 2006;66:1025-1032.